Table 1.
FACS Profiles of Anti-CD34 and Anti-JL1 mAb Immunofluorescence in Leukemia
| Type of leukemia | Percent of JL1+ cases | Percent of CD34+ cases | Percent of CD34+ JL1+ cases |
|---|---|---|---|
| AML | 90.1 (82*/91†) | 83.5 (76/91) | 76.9 (67/91) |
| M0 | 33.3 (1/3) | 100.0 (3/3) | 33.3 (1/3) |
| M1, M2 | 97.4 (38/39) | 92.3 (36/39) | 89.7 (35/39) |
| M3 | 100.0 (7/7) | 42.9 (3/7) | 42.9 (3/7) |
| M4, M5 | 84.4 (27/32) | 81.3 (26/32) | 68.8 (22/32) |
| Others‡ | 90.0 (9/10) | 80.0 (8/10) | 70.0 (7/10) |
| Non-T-ALL | 80.9 (55/68) | 64.7 (44/68) | 61.8 (42/68) |
| CD10+ | 90.6 (48/53) | 73.6 (39/53) | 67.9 (36/53) |
| CD10− | 83.3 (5/6) | 66.7 (4/6) | 66.7 (4/6) |
| sIg+ | 22.2 (2/9) | 11.1 (1/9) | 11.1 (1/9) |
| T-ALL | 87.0 (20/23) | 70.0 (16/23) | 60.9 (14/23) |
| Acute biphenotypic leukemia | 100.0 (13/13) | 84.6 (11/13) | 84.6 (11/13) |
| CML in blast crisis | 84.6 (11/13) | 92.3 (12/13) | 84.6 (11/13) |
| Total | 87.0 (181/208) | 76.4 (159/208) | 71.2 (148/208) |
*No. of positive cases.
†No. of cases tested.
‡Others included M6 (acute erythroleukemia), M7 (acute megakaryocytic leukemia), MDS (myelodysplasic syndromes), etc.
AML (acute myelogenous leukemia); M0 (acute myelogenous leukemia with minimal differentiation); M1 (acute myeloblastic leukemia without maturation); M2 (acute myeloblastic leukemia with maturation); M3 (acute promyelocytic leukemia); M4 (acute myelomonocytic leukemia); M5 (acute monocytic leukemia); non-T-ALL (non-T-cell acute lymphoblastic leukemia); T-ALL (T-cell acute lymphoblastic leukemia); CML (chronic myeloid leukemia).